Clinical Trial

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, or other anti-cancer treatment is required, or the Sponsor ends the study, whichever occurs first.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-01.
Status change: Not Yet Recruiting → Recruiting 2024-11-05
Trial Details
NCT Number NCT05983523
Lead Sponsor PharmaEngine
Conditions Advanced Solid Tumor, Metastatic Solid Tumor
Enrollment 54 participants
Start Date 2024-03-27
Primary Completion 2027-02-25 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-07